MedTrace Logo

Fructose Intestinal Gluconeogenesis

NCT07209202 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-06

No results posted yet for this study

Summary

This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.

Conditions

  • Healthy Participants
  • Obese But Otherwise Healthy Participants

Interventions

OTHER

High fructose meal

Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.

OTHER

Low fructose meal

55% total carbohydrate (6% fructose), 30% fat, 15% protein.

OTHER

13C labeled fructose, oral

Tracer amount of 13C labeled fructose administered orally in the meals.

OTHER

13C labeled fructose, intravenous

Tracer amount of 13C fructose administered intravenously

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Touro University, California

    lead OTHER

Principal Investigators

  • Jean-Marc Schwarz, PhD · Touro University, California

  • Grace M Jones, PhD · Touro University, California

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07209202 on ClinicalTrials.gov